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Strengths and limitations of this study
 ► This is the first study to validate the recording of bul-
lous pemphigoid and pemphigus vulgaris in primary 
healthcare records in England.
 ► The study involved a large sample size and the ap-
plication of algorithms to identify both primary care 
and benchmark hospital inpatient diagnoses.
 ► Blistering diagnoses recorded in hospital inpatient 
records were regarded as the benchmark diagnosis, 
but may be subject to misclassification.
AbStrACt
Objectives The validity of bullous pemphigoid and 
pemphigus vulgaris recording in routinely collected 
healthcare data in the UK is unknown. We assessed the 
positive predictive value (PPV) for bullous pemphigoid 
and pemphigus vulgaris primary care Read codes in the 
Clinical Practice Research Datalink (CPRD) using linked 
inpatient data (Hospital Episode Statistics (HES)) as the 
diagnostic benchmark.
Setting Adult participants with bullous pemphigoid 
or pemphigus vulgaris registered with HES- linked 
general practices in England between January 1998 
and December 2017. Code- based algorithms were used 
to identify patients from the CPRD and extract their 
benchmark blistering disease diagnosis from HES.
Primary outcome measure The PPVs of Read codes for 
bullous pemphigoid and pemphigus vulgaris.
results Of 2468 incident cases of bullous pemphigoid 
and 431 of pemphigus vulgaris, 797 (32.3%) and 85 
(19.7%) patients, respectively, had a hospitalisation record 
for a blistering disease. The PPV for bullous pemphigoid 
Read codes was 93.2% (95% CI 91.3% to 94.8%). Of the 
bullous pemphigoid cases, 3.0% had an HES diagnosis 
of pemphigus vulgaris and 3.8% of another blistering 
disease. The PPV for pemphigus vulgaris Read codes 
was 58.5% (95% CI 48.0% to 68.9%). Of the pemphigus 
vulgaris cases, 24.7% had an HES diagnosis of bullous 
pemphigoid and 16.5% of another blistering disease.
Conclusions The CPRD can be used to study bullous 
pemphigoid, but recording of pemphigus vulgaris needs to 
improve in primary care.
IntrOduCtIOn
Bullous pemphigoid and pemphigus vulgaris 
are rare autoimmune blistering diseases 
characterised by blistering of the skin and 
mucous membrane and associated with high 
mortality.1 2 There is a continued need to 
understand the causes, natural history and 
disease associations in order to better inform 
patients and plan treatment. However, there is 
a scarcity of recent epidemiological research 
on these distinct diseases in the UK and 
many unanswered questions. Furthermore, 
interpretation of available evidence is limited 
by the poor external validity and lack of power 
that are a feature of hospital- based studies.3–6
Routinely collected electronic healthcare 
records (EHR) may offer an excellent oppor-
tunity to examine bullous pemphigoid and 
pemphigus vulgaris at population level due to 
the availability of data on a large number of 
patients that are broadly representative of the 
UK population.7 Furthermore, the presence 
of prescription data allows the important 
association between possible drug exposure 
and bullous pemphigoid to be established, 
and longitudinal follow- up allows long- term 
outcomes to be assessed.8 However, as EHRs 
were created for clinical purposes, and not 
directly for research, it is essential to establish 
the validity of the diagnoses of interest.9
Diagnoses of bullous pemphigoid or 
pemphigus vulgaris are usually made in 
secondary care and entered into the primary 
care records by general practitioners (GP) 
or other practice staff using Read codes. 
Read codes have been used previously to 
identify patients with bullous pemphigoid 
and pemphigus vulgaris in EHRs, but have 
not been validated.2 8 10 11 A previous study 
examined the incidence of bullous pemphi-
goid and pemphigus vulgaris in the UK and 
found that the average age of patients with 
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pemphigus vulgaris was older than observed in other 
studies.2 Furthermore, it coincided with the peak age for 
bullous pemphigoid, suggesting that pemphigus vulgaris 
Read codes may not be accurate and that, in some cases, 
bullous pemphigoid was misclassified as pemphigus 
vulgaris.
Due to the linkage between primary and secondary 
care data, we now have the opportunity to externally vali-
date bullous pemphigoid and pemphigus vulgaris Read 
codes. This study aimed to determine the positive predic-
tive value (PPV) for bullous pemphigoid and pemphigus 
vulgaris primary care diagnostic Read codes in Clinical 
Practice Research Datalink (CPRD) using linked inpatient 
data (Hospital Episode Statistics; HES) as the benchmark.
MethOdS
Study design
This was a cohort study to validate Read codes for bullous 
pemphigoid and pemphigoid vulgaris in the CPRD. 
We followed the guidelines for the reporting of studies 
conducted using observational routinely collected health 
data.12
data sources
Clinical Practice Research Datalink
The CPRD GOLD is a longitudinal database of UK general 
practices using the Vision software system. It contains 
anonymised healthcare records from 1987 onwards for 
approximately 17 million patients with a current coverage 
of approximately 2.7 million (4%) of the UK popula-
tion. Routinely collected data within the CPRD include 
demographic and clinical information.7 Symptoms and 
diagnoses, generated from primary care consultations 
or obtained from hospital discharge or specialist clinic 
letters, are entered by GPs or other practice staff using 
Read codes.13
The data in the CPRD have repeatedly been shown to 
be of good research quality.14 At a practice level, partici-
pating practices are assigned an ‘up- to- standard’ date on 
completion of regular audits confirming data quality. At 
the patient level, records are assessed and patients are 
deemed ‘acceptable’ if data checks indicate that their 
record meets prespecified quality standards.
Hospital Episode Statistics
HES admitted patient care data are available for approxi-
mately 75% of English practices, covering over 10 million 
patients, that have consented to provide patient- level 
information from linked resources.15 Linkage is based on 
each patient’s National Health Service number, which is 
unique and remains unchanged through their lifetime, 
along with other identifiers (eg, gender, date of birth, 
postcode).16 HES admitted patient care contains demo-
graphic and clinical data, coded using the International 
Classification of Diseases Version 10 (ICD-10).17 18 Each 
hospital episode is attributed one primary diagnosis, 
while comorbidities and other diagnoses are recorded as 
secondary diagnoses.
Study population
Adult men and women registered with 410 HES- linked 
general practices in England during the period of 1 
January 1998 to 31 December 2017 were included.
Case definition of bullous pemphigoid and pemphigus vulgaris
Diagnostic Read code lists for bullous pemphigoid and 
pemphigus vulgaris were developed based on the expert 
opinion of two consultant dermatologists (KEH and SML) 
and a GP (JHC). Bullous pemphigoid Read codes were 
classed as specific (M145000, ‘bullous pemphigoid’) or 
broad (M145.00, ‘pemphigoid’; M145z00, ‘pemphigoid 
not otherwise specified’). Likewise, pemphigus vulgaris 
codes were grouped as specific (M144600, ‘pemphigus 
vulgaris’; M144500, ‘pemphigus vegetans’) or broad 
(M144.00, ‘pemphigus’; M144z00, ‘pemphigus not other-
wise specified’).
Clinical data were sought for all patients who had at 
least one specific or broad Read code for bullous pemphi-
goid or pemphigus vulgaris. Based on clinical experience, 
it was considered inappropriate to define a case based on 
the first recording of bullous pemphigoid or pemphigus 
vulgaris without taking into account subsequent Read 
code entries for blistering diseases which were some-
times multiple and conflicting. A code- based algorithm 
(figure 1) was therefore applied to determine the most 
likely diagnosis. The date of diagnosis was taken as the 
first recording of the Read code generated through the 
algorithm. Patients were considered cases if their most 
likely blistering disease diagnosis, generated through 
the algorithm, was bullous pemphigoid or pemphigus 
vulgaris. Those with diagnoses for other blistering diseases 
were excluded. Further information about the blistering 
disease codes used is available in online supplementary 
table 1.
Observation period
The observation period commenced on the latest of (1) 
1 January 1998, (2) the patient’s 18th birthday, (3) 1 year 
after the patient was registered with their current general 
practice, or (4) the practice’s up- to- standard date. A 1 
year lag period from the patient’s registration date with 
their GP was imposed to minimise the risk of prevalent 
cases being identified as incident cases.19
The observation period terminated on the earliest of 
(1) 31 December 2017, (2) the date of death, (3) the 
date the patient left the practice, (4) the practice’s last 
data collection date, and (5) the most recent linkage date 
between CPRD and HES.
Validation of bullous pemphigoid and pemphigus vulgaris 
read codes
For people with a bullous pemphigoid or pemphigus 
vulgaris diagnosis in primary care, we identified those 
with a hospital inpatient episode recording a blistering 
disease (ICD-10: L10, L12, L13) as a primary or secondary 
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Figure 1 The code- based algorithm used to determine 
a diagnosis of bullous pemphigoid or pemphigus vulgaris 
using Read codes in the Clinical Practice Research Datalink 
(CPRD). The date of diagnosis was taken as the first 
recording of the Read code generated through the algorithm.
Figure 2 Code- based algorithm used to determine a 
benchmark diagnosis from secondary care HES data in 
patients identified from Clinical Practice Research Datalink 
(CPRD) as having bullous pemphigoid or pemphigus vulgaris. 
The date of diagnosis was taken as the first recording of the 
diagnosis generated through the algorithm. HES, Hospital 
Episode Statistics; ICD-10, International Classification of 
Diseases Version 10.
diagnosis at any point. Due to the presence of multiple 
records per patient, an algorithm based on clinical knowl-
edge (figure 2) was applied to determine one secondary 
care ICD-10 blistering disease diagnosis per patient, 
which was regarded as their benchmark diagnosis. The 
date of diagnosis was taken as the first recording of the 
diagnosis generated through the algorithm. The distri-
bution of the benchmark diagnoses was examined for 
bullous pemphigoid and pemphigus vulgaris cases identi-
fied in the CPRD.
ICD-10 codes L12.0 (bullous pemphigoid) and L12.9 
(pemphigoid, unspecified) were classed as ‘bullous 
pemphigoid’. ICD-10 codes L10.0 (pemphigus vulgaris), 
L10.1 (pemphigus vegetans) and L10.9 (pemphigus, 
unspecified) were classed as ‘pemphigus vulgaris’. All 
other blistering disease ICD-10 codes and where the HES 
algorithm generated an uncertain diagnosis were classed 
as ‘other’. See online supplementary table 1 for the full 
list of blistering disease codes.
Statistical analysis
The sex and age of bullous pemphigoid and pemphigus 
vulgaris cases were presented descriptively. Age was 
assessed for normality visually, the mean (SD) or median 
(IQR) was calculated as appropriate. For bullous pemphi-
goid and pemphigus vulgaris cases with a hospital 
inpatient record for a blistering disease, the PPV and 
associated 95% CI were calculated for the specific, broad 
and combined Read codes for bullous pemphigoid 
and pemphigus vulgaris against their benchmark diag-
nosis from HES. The blistering disease secondary care 
diagnoses were presented descriptively. Analyses were 
conducted using Stata V.16 (StataCorp).
Sensitivity analysis
The most recent Read code was used for patients with 
conflicting Read codes (ie, patients who did not have a 
more commonly occurring Read code; last step of algo-
rithm, figure 1). This was done under the assumption that 
diagnoses are likely to be refined over time and the most 
recent code was likely to be most accurate. The impact 
of this assumption was investigated through a sensitivity 
analysis comparing the PPVs for bullous pemphigoid and 
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Figure 3 Age at diagnosis (years) in patients with bullous pemphigoid (n=2468) and pemphigus vulgaris (n=431). A peak is 
observed at 80–84 years for bullous pemphigoid recording, while two peaks are seen for pemphigus vulgaris; one at 50–54 and 
a later, and slightly higher, peak at 75–79 years. CPRD, Clinical Practice Research Datalink.
pemphigus vulgaris in all cases versus excluding patients 
with conflicting Read codes.
Patient and public involvement
The study was supported by a patient and public advi-
sory group which provided input to the programme of 
research. We met with this advisory group on a regular 
basis for the duration of the study. The advisory group 
commented on the design of the study and, at the end of 
the study, they commented on the findings and suggested 
how to share the findings with the public.
reSultS
Study population
A total of 2899 incident cases of bullous pemphigoid 
and pemphigus vulgaris were identified in HES- linked 
practices using the algorithm (see online supplemen-
tary figure 1 for patient flow diagram). The median 
(IQR) age at diagnosis was 81 years (73–87) for the 2468 
bullous pemphigoid cases, and 64 years (48–77) for the 
431 pemphigus vulgaris cases. The peak age for bullous 
pemphigoid recording was around 80–84 years. In 
contrast, two peaks were observed for pemphigus vulgaris 
case recording, one at 50–54 years and a later, slightly 
higher, peak at 75–79 years (figure 3).
The proportion of women was 56.7% and 64.5% for 
bullous pemphigoid and pemphigus vulgaris, respec-
tively. Of the 2899 cases, 223 (9.0%) had at least one 
conflicting Read code indicative of another blistering 
disease or a general blistering disease code (eg, ‘bullous 
dermatoses’).
Validation of bullous pemphigoid and pemphigus vulgaris 
diagnostic codes
Of 2899 incident cases of bullous pemphigoid or 
pemphigus vulgaris, 882 (30.4%) had at least one hospital 
episode recording a blistering disease diagnosis. In 
44.0% of these patients, it was a primary diagnosis. The 
remaining 2017 (69.6%) patients did not have any hospi-
talisation records listing a blistering disease diagnosis and 
were not analysed in the validation study.
Using the algorithm, 10 patients (1.1%) had an 
uncertain HES diagnosis and were classified as ‘other’. 
The blistering disease codes of these cases are shown in 
online supplementary table 2. The distribution of HES 
diagnoses for the bullous pemphigoid and pemphigus 
vulgaris incident cases and PPV for bullous pemphigoid 
and pemphigus vulgaris Read codes are shown in table 1.
Bullous pemphigoid
Of 2468 incident cases, 797 (32.2%) had a hospital-
isation record for a blistering disease. Cases were most 
commonly coded with specific (69.1%) rather than broad 
(30.8%) Read codes. The PPV of the bullous pemphi-
goid Read codes combined was 93.2% (95% CI 91.3% to 
94.8%). Broad Read codes had a lower PPV (87.8%, 95% 
CI 83.1% to 91.4%) than the specific codes (95.6%, 95% 
CI 93.6% to 97.1%).
Pemphigus vulgaris
Of 431 incident cases, 85 (19.7%) had a hospitalisation 
record for a blistering disease. Cases were more commonly 
coded with broad disease codes (74.1%) than specific 
codes (25.9%). The PPV of the pemphigus vulgaris Read 
codes combined was 58.8% (95% CI 48.0% to 68.9%). 
Specific Read codes showed a higher PPV (81.8%, 95% 
CI 58.8% to 93.4%) than broad codes (50.8%, 95% CI 
38.4% to 63.1%).
Sensitivity analysis
The sensitivity analyses excluding the 223 patients with 
conflicting Read codes resulted in broadly unchanged 
PPVs. The PPV for the 776 patients with consistent 
bullous pemphigoid Read codes was 93.6% (95% CI 
91.6% to 95.1%). The PPV for the 75 patients with consis-




A benchmark, secondary care diagnosis of pemphigus 
vulgaris or another blistering disease diagnosis was made 
for 24 (3.0%) and 30 (3.8%) of the 797 cases, respectively. 
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Table 1 Distribution of benchmark blistering disease diagnoses for bullous pemphigoid and pemphigus vulgaris incident 
cases identified in the CPRD, shown with the PPV (95% CI) for specific, broad and combined Read codes for each disease
CPRD Read code
Hospital episode diagnosis (benchmark)






Specific (M145000) 527 (95.6%) 12 (2.2%) 12 (2.2%) 551 95.6 (93.6 to 97.1)
Broad (M145.00, 
M145z00)
216 (87.8%) 12 (4.9%) 18 (7.3%) 246 87.8 (83.1 to 91.4)




2 (9.1%) 18 (81.8%) 2 (9.1%) 22 81.8 (58.8 to 93.4)
Broad (M144.00, 
M144z00)
19 (30.2%) 32 (50.8%) 12 (19.1%) 63 50.8 (38.4 to 63.1)
Total 21 (24.7%) 50 (58.8%) 14 (16.5%) 85 58.8 (48.0 to 68.9)
ICD-10 codes L10.0 (pemphigus vulgaris), L10.1 (pemphigus vegetans) and L10.9 (pemphigus, unspecified) are classed as a hospital episode 
diagnosis of ‘pemphigus vulgaris’. ICD-10 codes L12.0 (bullous pemphigoid) and L12.9 (pemphigoid, unspecified) are classed as ‘bullous 
pemphigoid’. All other blistering disease ICD-10 codes and where the HES algorithm generated an uncertain diagnosis (n=7 for bullous 
pemphigoid and n=3 for pemphigus vulgaris) are classed as ‘other’.
CPRD, Clinical Practice Research Datalink; HES, Hospital Episode Statistics; ICD-10, International Classification of Diseases Version 10; PPV, 
positive predictive value.
The most common ‘other’ benchmark diagnosis was 
cicatricial pemphigoid (n=11, 36.7%; L12.1, mucous 
membrane pemphigoid). Other benchmark diagnoses 
were other pemphigus (L10.8), other pemphigoid 
(L12.8) and bullous disorder unspecified (L13.9).
Pemphigus vulgaris
Of the 85 cases with a primary care diagnosis for 
pemphigus vulgaris, 21 (24.7%) had an HES diagnosis 
for bullous pemphigoid and 14 (16.5%) for another blis-
tering diagnosis. The most common ‘other’ secondary 
care diagnosis was for pemphigus foliaceus (n=6, 42.9%; 
L10.2). Other benchmark diagnoses were drug- induced 
pemphigus (L10.5), cicatricial pemphigoid (L12.1), 
dermatitis herpetiformis (L13.0), subcorneal pustular 




Incident diagnoses of bullous pemphigoid and pemphigus 
vulgaris identified in the CPRD were compared with the 
blistering disease diagnoses made in secondary care 
(benchmark diagnosis). Diagnoses were recorded in the 
CPRD using specific (M145000, ‘bullous pemphigoid’; 
M144600, ‘pemphigus vulgaris’; M144500, ‘pemphigus 
vegetans’) or broad (M145.00, ‘pemphigoid’; M145z00, 
‘pemphigoid not otherwise specified’; M144.00, 
‘pemphigus’; M144z00, ‘pemphigus not otherwise spec-
ified’) Read codes. Overall, 882 (30.4%) patients iden-
tified in the CPRD also had hospitalisation records for a 
blistering disease. We found good consistency between 
primary and secondary care diagnoses for bullous 
pemphigoid and a high PPV for bullous pemphigoid 
Read codes (93.2%). The PPV for the specific Read codes 
for bullous pemphigoid was higher (95.6%) than that of 
the broad Read codes (87.8%) and captured a greater 
proportion of cases (69.1%). The consistency was not as 
good for pemphigus vulgaris, with a moderate PPV for 
pemphigus vulgaris Read codes (58.8%). The majority 
of cases of pemphigus vulgaris were coded with broad 
disease codes (74.1%) with lower PPVs (50.8%). The 
PPV for the specific pemphigus vulgaris Read codes was 
higher (81.8%), but captured only a subset of the popu-
lation (25.9%).
Our study shows that the codes for bullous pemphi-
goid in the CPRD appear to be capturing people who 
have the disease and cases reflect expected age distribu-
tions. Approximately 93% of bullous pemphigoid cases 
identified using the algorithm are likely to have bullous 
pemphigoid. In contrast, only 59% of pemphigus vulgaris 
cases identified are likely to have pemphigus vulgaris, with 
almost 25% probably suffering from bullous pemphigoid. 
The probable misclassification of bullous pemphigoid 
cases as pemphigus vulgaris likely explains the peak of 
pemphigus vulgaris codes observed at 75–79 years, coin-
ciding with the peak age for bullous pemphigoid. Conse-
quently, the use of data from the CPRD for pemphigus 
vulgaris research may be limited.
Comparability with other studies
To date, no studies have validated Read codes and only 
two studies have validated ICD codes for bullous pemphi-
goid or pemphigus vulgaris using EHRs (table 2). The 
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Table 2 Published validation studies of bullous pemphigoid or pemphigus vulgaris diagnostic codes in EHR
Publication Disease Classification EHR Population Validation method PPV (95% CI)






















Manual review of 
outpatient and inpatient 
records. Diagnosis 
was confirmed by ≥2 
indicators of disease:
 ► Clinical diagnosis
 ► Biopsy histology
 ► Direct 
immunofluorescence


































Manual review of 
immunopathological 
and histopathological 
registries and medical 
records. Diagnosis was 
confirmed by:
 ► Clear clinical 
history and physical 
examination, and
 ► Positive ELISA, or






*Pemphigus vulgaris, pemphigus vegetans, pemphigus foliaceus, pemphigus erythematosus, paraneoplastic pemphigus and drug- induced 
pemphigus.
EHR, electronic healthcare record; ICD-10, International Classification of Diseases Version 10; PPV, positive predictive value.
PPV for bullous pemphigoid Read codes in the CPRD is 
comparable to that found in routinely collected health-
care data from Sweden (National Patient Register; 92%), 
which validated bullous pemphigoid ICD-10 codes 
using information from pathology registers and medical 
records.20 In contrast, the PPVs for bullous pemphigoid 
and pemphigus vulgaris Read codes were lower in the 
CPRD than those presented for the electronic medical 
records in the USA (Northwestern Medicine Electronic 
Data Warehouse; 99% for bullous pemphigoid and 
100% for pemphigus ICD-9 codes).21 However, Hsu et 
al21 presented the PPV only for those cases with multiple 
disease codes for the same disease, and not for those 
with a single code or those with conflicting codes. The 
stringency of the case definition may explain the higher 
PPV found, but would not be suitable if the study aim was 
to identify all (or nearly all) cases in a population- based 
study. Furthermore, the work included several subsets of 
pemphigus disease, rather than just pemphigus vulgaris, 
and did not provide any indication of potential misclas-
sification between different pemphigus diseases. Further 
comparisons between our study and the aforementioned 
studies are hindered as the studies validated ICD-9 and 
ICD-10 codes rather than Read codes. However, the 
evidence indicates that routinely collected healthcare 
data may be a valuable source for investigating bullous 
pemphigoid. The role of such data sources for investi-
gating pemphigus vulgaris remains uncertain.
Strengths and limitations
The strengths of the present work include a large sample 
size and the application of algorithms to identify both 
primary care and benchmark hospital inpatient diag-
noses. One- off occurrences of a bullous pemphigoid or 
pemphigus vulgaris code in the presence of alternate blis-
tering disease codes may indicate a working diagnosis that 
is later revised or may be incorrect due to a typographical 
error or oversight. Based on clinical knowledge, using an 
algorithm that prioritised diagnoses with multiple entries 
and consistent coding was considered to help reduce the 
impact of recording errors.
The study is limited by the inability to calculate the 
negative predictive value, sensitivity and specificity of the 
Read codes. Additionally, HES diagnoses were regarded 
as the benchmark in the present study, but may be inac-
curate. The benchmark diagnoses may be subject to 
misclassification bias due to a heterogeneous group of 
pemphigoid variants (eg, non- bullous pemphigoid, which 
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presents with intense itching, a polymorphic rash, but no 
blisters), alternative approaches to making a diagnosis 
and differences in the diagnostic tests used to confirm 
the diagnosis.22 23 Nevertheless, this was regarded as the 
best approach as external validation with hospital notes 
was not possible. Finally, validation was only possible 
for a third of patients and it may be that patients with 
a hospitalisation record for a blistering disease are not 
representative of the overall population of patients as 
they are more likely to have severe disease and associated 
comorbidities.
Possible explanations for findings
Almost a quarter of patients with Read codes indicative 
of pemphigus vulgaris in the CPRD may have bullous 
pemphigoid. Such misclassification may be due to unfa-
miliarity with the disease by GPs and administrators or 
typographical error. Pemphigus and pemphigoid sound 
similar and, to those unfamiliar with the diseases, the 
terms may be thought to be interchangeable. Addition-
ally, the lower prevalence of pemphigus vulgaris in the 
population might explain why lower PPVs were reported 
for pemphigus vulgaris than bullous pemphigoid.
Inclusion of broad Read codes also contributes to the 
apparent misclassification seen. For example, although 
we have assumed that broad pemphigoid codes identify 
a patient with bullous pemphigoid, such a code could 
correctly be attributed to a patient with a different 
pemphigoid disease, such as mucous membrane 
pemphigoid. Similarly, a patient with pemphigus foli-
aceus could correctly be attributed a broad pemphigus 
code. Correct attribution of broad Read codes to 
patients with pemphigoid or pemphigus diseases other 
than bullous pemphigoid or pemphigus vulgaris likely 
explains the lower PPVs seen for the broad versus 
specific Read codes.
Possible implications for future research
Implementation of an algorithm allows a consistent and 
reproducible approach to identifying patients in the pres-
ence of multiple, sometimes conflicting, blistering disease 
codes. The algorithm was developed based on clinical 
expertise and future research should be conducted to 
test alternate approaches and determine the sensitivity, 
specificity and negative predictive value.
Focused efforts on increasing GPs’ awareness of auto-
immune blistering skin disorders and providing resources 
for how to differentiate between bullous pemphigoid 
and pemphigus vulgaris may be required to improve 
the recording of the diseases in the CPRD. Currently, 
the discrepant codes observed complicate the examina-
tion of pemphigus vulgaris in the CPRD, and may also 
underestimate the true incidence of bullous pemphigoid. 
However, only a minor proportion of the population with 
a benchmark diagnosis for bullous pemphigoid (<3%) 
were miscoded as pemphigus vulgaris in primary care, 
and the effect may therefore be minimal.
COnCluSIOn
The PPVs of Read codes for bullous pemphigoid are high 
in the CPRD, but only moderate for pemphigus vulgaris. 
The CPRD is a useful data source for bullous pemphi-
goid research, but may have lower utility for pemphigus 
vulgaris. We suggest future studies of bullous pemphigoid 
in the CPRD should consider using this study’s validated 
Read code list to identify cases. EHRs, such as the CPRD, 
could be an invaluable resource for the examination of 
a rare disease such as pemphigus vulgaris, but there is a 
need for more accurate recording of diagnoses in primary 
care.
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